Pharma BD Deal Intelligence

Sanofi SA / Genzyme Corporation

2010 · Acquisition/Merger · $18.5B · Complete

Sanofi's ~$18.5B bid for Genzyme delivered exactly the durable rare-disease franchise it wanted—Cerezyme, Fabrazyme, and later Lemtrada gave Sanofi a lasting biologics/specialty pivot away from small-molecule exposure. The win came with a scar: a bad-faith CVR dispute over the deal's contingent payout cost Sanofi $315M in litigation.

CALLED IT — OFF BY 19
Full analysis, sources & comparables →

The coverage arc

Aug 29, 2010 Sanofi-Aventis (6-K Exhibit) Bullish

$69 per share all-cash offer represents immediate and certain value and a significant premium for Genzyme shareholders — 38% over Genzyme's unaffected share…

Oct 04, 2010 WBUR Neutral

Genzyme management rejected the $69-per-share hostile bid as undervalued; CEO Henri Termeer argued shareholders deserved closer to $80 per share, saying 'They…

Oct 31, 2019 BioPharma Dive Bearish

Sanofi paid $315M to settle claims it slowed Lemtrada's development to avoid CVR payouts of $708M-$3.8B; FDA approval missed targets by 8+ months and sales…

Source summaries from our enrichment pipeline; follow links for originals.

All 9 sources with sentiment breakdown →

Sanofi-aventis submitted a non-binding proposal to acquire Genzyme for approximately $18.5B ($69/share) on August 29, 2010. Final definitive agreement reached February 16, 2011 at $74/share plus CVR (~$20.1B total). Closed April 8, 2011.

Did it work? Outcome assessment

Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Genzyme generated ~$4bn in net sales in 2010 and became Sanofi's global rare-disease center of excellence (Sanofi Genzyme). The core rare-disease franchise (Cerezyme, Fabrazyme, Myozyme) recovered after the Framingham plant won FDA/EMA approval in Jan 2012 and contributed to 2011+ results. The Lemtrada-linked contingent value rights (CVRs, ticker GCVRZ) largely failed their milestones — Sanofi later paid a $315mm settlement (2020) over claims it slowed Lemtrada — but the unde
Pipeline outcome
Mixed
Rare-disease enzyme replacement therapies stabilized and grew once manufacturing was fixed, and MS assets Aubagio and Lemtrada launched. However, Lemtrada substantially underperformed the CVR sales/approval milestones, and the FDA approval missed the CVR target date by more than eight months, denying former shareholders payouts and triggering litigation.

Key facts

Disease & market context

Lysosomal Storage Disorders (Gaucher & Fabry disease)

Disease Overview

Gaucher and Fabry are inherited lysosomal storage disorders caused by deficient enzymes (glucocerebrosidase, alpha-galactosidase A) leading to substrate accumulation in organs. Both are ultra-rare, lifelong, and treatable only by chronic enzyme replacement therapy (ERT). Manufacturing complexity and small patient pools made Genzyme's franchise highly defensible.

Competitive Landscape

At deal time (2010-2011), Genzyme dominated lysosomal storage with Cerezyme (imiglucerase) for Gaucher and Fabrazyme (agalsidase beta) for Fabry — both monopolies disrupted only by Genzyme's own 2009 Allston Landing manufacturing contamination, which created shortages and let Shire (Vpriv/velaglucerase, FDA-approved Feb 2010) and Pfizer/Protalix (Elelyso/taliglucerase, approved 2012) take share. In Fabry, Shire's Replagal (agalsidase alfa) competed ex-US but was withdrawn from US filing in 2012. Sanofi paid up specifically for the rare-disease franchise plus the MS asset Lemtrada (alemtuzumab, then awaiting FDA filing) — the CVR mechanism allocated up to $14/share in milestones tied to Cerezyme/Fabrazyme 2011 production recovery and Lemtrada approval/sales. The deal converted Sanofi from a primary-care/vaccines house into a biotech-led rare-disease leader and seeded the spinout that became Sanofi Genzyme.

Multiple Sclerosis

Disease Overview

Multiple sclerosis is an autoimmune demyelinating disease of the CNS that causes relapsing or progressive neurologic disability. It typically presents in adults aged 20-50 and disproportionately affects women. Disease-modifying therapies suppress relapses but do not reverse existing damage.

Competitive Landscape

In 2010-2011, the MS market was dominated by interferon-betas (Avonex/Biogen, Rebif/Merck KGaA-Pfizer, Betaseron/Bayer) and Copaxone (glatiramer/Teva), with Tysabri (natalizumab, Biogen-Elan) carving the high-efficacy niche despite PML risk. Novartis' Gilenya (fingolimod) had just become the first oral DMT (Sept 2010), and Biogen's Tecfidera (dimethyl fumarate) was approaching filing. Genzyme's Lemtrada (alemtuzumab) — already marketed at higher doses as Campath in CLL — was being repositioned as an induction-style anti-CD52 antibody promising long-lived remission from short dosing courses. Sanofi structured the CVR specifically because buy- and sell-side disagreed sharply on Lemtrada's commercial peak; the FDA ultimately rejected the first BLA in late 2013 before approving in Nov 2014 with a restricted REMS, validating analyst skepticism and triggering a decade of CVR litigation that Sanofi settled for $315M in 2019.

Related deals — scored

DealYearValueOutcome
Sanofi SA / Genzyme Corporation (this deal)2010$18.5B75
Sanofi SA / Regeneron Pharmaceuticals, Inc.2007$1.0B97
Sanofi SA / Synthelabo S.A.1998$11.0B84
Sanofi SA / Genzyme Corporation2011$20.1B84
Sanofi SA / Amunix Pharmaceuticals Inc.2021$1.2B76
Sanofi SA / Translate Bio Inc.2018$805M73
Sanofi SA / Protein Sciences Corp.2017$650M72

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →